"Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)."
Cohen et al., 2019, Expert Opinion on Biological Therapy Volume 19 Issue 10, 1097-1105
1. Understand the data which led to FDA-approval of the first interchangeable biosimiliar antibody, Cyltezo (adalimumab-adbm)
2. Understand the differences in structure, efficacy and safety between Cyltezo (adalimumab-adbm) and Adalimumab in rheumatoid arthritis
01/18/2022 - 8:30am to 9:30am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Didem Saygin M.D.